Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
Combining chemotherapy with interferon alfa may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining bexarotene with interferon
alfa in treating patients who have cutaneous T-cell lymphoma.